Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Principal Accounting Officer John Militello resigns effective July 7, 2026, citing pursuit of other opportunities.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Principal Accounting Officer John Militello resigns effective July 7, 2026, citing pursuit of other opportunities
- Joseph Manhede assumes Principal Accounting Officer duties July 8, 2026, ensuring immediate succession
- Manhede brings prior controller experience across Outlook Therapeutics, Amneal Pharmaceuticals, Unilife, and Celator Pharmaceuticals
- No new compensation, related-party transactions, or family relationships disclosed for Manhede
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.